Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IGBA seeks framework waiving bridging trials

Executive Summary

A new international regulatory framework for waiving biosimilar bridging studies has been proposed by the International Generic and Biosimilar Medicines Association (IGBA) in comments submitted to a US Food and Drug Administration (FDA) docket on facilitating competition and innovation in the biological products marketplace. This would allow such studies to be waived “in specific circumstances, based on core scientific and regulatory principles established for current products”. The IGBA’s call for a framework came in response to the FDA having asked for comments on what additional steps the agency could take “to facilitate multinational development programs that may include non-US-licensed comparators, to help support development of biosimilar products?” The FDA has invited comments via docket FDA-2018-N-2689 following a public hearing on biosimilar competition held in early September (Generics bulletin, 14 September 2018, page 8).


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts